1. Home
  2. CELC vs MVF Comparison

CELC vs MVF Comparison

Compare CELC & MVF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CELC
  • MVF
  • Stock Information
  • Founded
  • CELC 2011
  • MVF 1988
  • Country
  • CELC United States
  • MVF United States
  • Employees
  • CELC N/A
  • MVF N/A
  • Industry
  • CELC Medical Specialities
  • MVF Investment Bankers/Brokers/Service
  • Sector
  • CELC Health Care
  • MVF Finance
  • Exchange
  • CELC Nasdaq
  • MVF Nasdaq
  • Market Cap
  • CELC 440.0M
  • MVF 382.4M
  • IPO Year
  • CELC 2017
  • MVF N/A
  • Fundamental
  • Price
  • CELC $13.04
  • MVF $6.64
  • Analyst Decision
  • CELC Strong Buy
  • MVF
  • Analyst Count
  • CELC 6
  • MVF 0
  • Target Price
  • CELC $30.67
  • MVF N/A
  • AVG Volume (30 Days)
  • CELC 196.9K
  • MVF 162.8K
  • Earning Date
  • CELC 08-13-2025
  • MVF 01-01-0001
  • Dividend Yield
  • CELC N/A
  • MVF 4.11%
  • EPS Growth
  • CELC N/A
  • MVF N/A
  • EPS
  • CELC N/A
  • MVF N/A
  • Revenue
  • CELC N/A
  • MVF N/A
  • Revenue This Year
  • CELC N/A
  • MVF N/A
  • Revenue Next Year
  • CELC N/A
  • MVF N/A
  • P/E Ratio
  • CELC N/A
  • MVF N/A
  • Revenue Growth
  • CELC N/A
  • MVF N/A
  • 52 Week Low
  • CELC $7.58
  • MVF $5.85
  • 52 Week High
  • CELC $19.77
  • MVF $7.19
  • Technical
  • Relative Strength Index (RSI)
  • CELC 60.10
  • MVF 48.92
  • Support Level
  • CELC $12.48
  • MVF $6.52
  • Resistance Level
  • CELC $13.60
  • MVF $6.70
  • Average True Range (ATR)
  • CELC 0.74
  • MVF 0.05
  • MACD
  • CELC 0.04
  • MVF 0.01
  • Stochastic Oscillator
  • CELC 75.91
  • MVF 63.89

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

About MVF Blackrock MuniVest Fund Inc.

Blackrock Munivest Fund Inc is an investment management firm. Its investment objective is to provide current income exempt from regular U.S. federal income tax. The company invests in various sectors such as Health; Transportation; Utilities; Education; Tobacco; Housing and others.

Share on Social Networks: